<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">Several investigated medical treatments for COVID-19 are known either to be safe or nonteratogenic in pregnancy. These include various immune modulators such as hydroxychloroquine/chloroquine, methylprednisolone/glucocorticoids, and the anti-viral medications lopinavir-ritonavir (
 <xref rid="bib69" ref-type="bibr">69</xref>, 
 <xref rid="bib70" ref-type="bibr">70</xref>, 
 <xref rid="bib71" ref-type="bibr">71</xref>, 
 <xref rid="bib72" ref-type="bibr">72</xref>, 
 <xref rid="bib73" ref-type="bibr">73</xref>). It is important to note that, although nonteratogenic, the use of glucocorticoids in pregnancy has been associated with diabetes, weight gain, preterm premature rupture of membranes, hypertension, and intrauterine growth restriction. Interferon therapy, often used in hepatitis C treatment, has been well established to be safe in pregnancy (
 <xref rid="bib74" ref-type="bibr">74</xref>). The use of convalescent plasma, or plasma derived from individuals who previously contracted COVID-19, has been shown to reduce disease sequela in those with severe disease (
 <xref rid="bib75" ref-type="bibr">75</xref>). Given that its risk profile should be similar to a blood transfusion, there are no overt contraindications in pregnancy.
</p>
